Summary: Properties and effects of sterol synthesis pathway inhibitors on EBOV entry and infection and on cholesterol accumulation in LE/Lys.

aabbreviations of target enzymes in cholesterol synthesis pathway: HMGCR, HMG CoA Reductase; FPPS, Farnesyl pyrophosphate synthase; d7R, Sterol delta-7 reductase; c14d8, Lanosterol C14-demethylase/sterol delta; d7/d14R, Sterol delta-7 and delta-14 reductase; SQLE, Squalene epoxidase; OSC, 2,3 Oxidosqualene cyclase; c14dM, Lanosterol C14-demethylase; d24R, Sterol delta-24 reductase.bdata for clomiphene are from Johansen et al., in revision; all other data are from Fig. 1.cdata from Fig. 2.ddata from Fig. 5; CHOL, cholesterol.eRo 48-8071 appeared to induce less CHOL accumulation than the other inhibitors scored ‘yes’ for this phenotype.fCAD, Cationic amphiphilic drug.gpKa and cLogP were calculated as described in the Methods section. All compounds highlighted in bold were shown to robustly block EBOV GP-mediated VLP entry (≥90% inhibition) and infection by authentic EBOV.